AlphaCentric Advisors LLC Makes New $231,000 Investment in Krystal Biotech, Inc. (NASDAQ:KRYS)

AlphaCentric Advisors LLC bought a new position in Krystal Biotech, Inc. (NASDAQ:KRYS) in the fourth quarter, Holdings Channel.com reports. The firm bought 1,474 shares of the company’s stock, valued at approximately $231,000.

A number of other hedge funds also recently made changes to their positions in KRYS. State Street Corp lifted its stake in Krystal Biotech by 9.0% in the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after purchasing an additional 119,936 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Krystal Biotech by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock valued at $107,714,000 after acquiring an additional 11,411 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of Krystal Biotech by 34.2% in the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock valued at $43,774,000 after acquiring an additional 62,178 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Krystal Biotech by 9.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 240,216 shares of the company’s stock valued at $43,727,000 after acquiring an additional 19,777 shares in the last quarter. Finally, Braidwell LP grew its position in Krystal Biotech by 57.4% during the 3rd quarter. Braidwell LP now owns 168,691 shares of the company’s stock worth $30,707,000 after acquiring an additional 61,512 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 14.10% of the company’s stock.

Krystal Biotech Price Performance

Shares of KRYS stock opened at $153.24 on Monday. The stock has a market capitalization of $4.41 billion, a PE ratio of 86.58 and a beta of 0.84. The business’s 50 day simple moving average is $158.61 and its 200 day simple moving average is $175.74. Krystal Biotech, Inc. has a one year low of $107.50 and a one year high of $219.34.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on KRYS shares. Chardan Capital reissued a “buy” rating and set a $212.00 price target on shares of Krystal Biotech in a research note on Wednesday, December 18th. Citigroup lifted their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, HC Wainwright restated a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a research report on Wednesday, December 18th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Krystal Biotech has a consensus rating of “Buy” and an average price target of $206.67.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).